Cargando…
Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study
SIMPLE SUMMARY: In this study, the rate of hepatocellular carcinoma (HCC) recurrence (HCC-R) after hepatitis C virus eradication by direct-acting antiviral (DAA) treatment was relatively high, corresponding to 63.8% (83/130) of the studied cases. The patients who electively received palliative treat...
Autores principales: | Tani, Joji, Senoh, Tomonori, Moriya, Akio, Ogawa, Chikara, Deguchi, Akihiro, Sakamoto, Teppei, Takuma, Kei, Nakahara, Mai, Oura, Kyoko, Tadokoro, Tomoko, Mimura, Shima, Fujita, Koji, Yoneyama, Hirohito, Kobara, Hideki, Morishita, Asahiro, Himoto, Takashi, Tsutsui, Akemi, Nagano, Takuya, Takaguchi, Koichi, Masaki, Tsutomu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125844/ https://www.ncbi.nlm.nih.gov/pubmed/34066708 http://dx.doi.org/10.3390/cancers13092257 |
Ejemplares similares
-
Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study
por: Tani, Joji, et al.
Publicado: (2020) -
Peg-IFNα-2a Contributed to HBs Antigen Seroclearance in a Patient with Chronic Hepatitis B Administered Nucleic Acid Analogs: A Three-year Follow-up
por: Tadokoro, Tomoko, et al.
Publicado: (2021) -
Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy
por: Oura, Kyoko, et al.
Publicado: (2023) -
Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion
por: Nomura, Takako, et al.
Publicado: (2019) -
Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study
por: Morishita, Asahiro, et al.
Publicado: (2022)